Actively Recruiting
Randomized Multinational Study Comparing MB11 Nivolumab Biosimilar and Opdivo Assessing Pharmacokinetics, Safety, and Effectiveness in Untreated Advanced Melanoma
Led by mAbxience Research S.L. · Updated on 2026-10-29
632
Participants Needed
86
Research Sites
96 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a randomized, multicenter, multinational, double-blind Phase 3 study comparing MB11, a proposed nivolumab biosimilar, with EU- and US-sourced Opdivo in adults with previously untreated advanced unresectable or metastatic melanoma. The study aims to evaluate and compare the pharmacokinetics, efficacy, safety, and immune response of MB11 versus Opdivo as first-line treatment. Participants receive one of three study drugs MB11, EU-Opdivo, or US-Opdivo. During the first 12 treatment cycles, each is given as a 3 mgkg intravenous infusion over 30 minutes every two weeks. From Cycle 13 onwards, dosing continues either at 3 mgkg IV every two weeks or a flat dose of 240 mg IV every two weeks. The study treatment period covers at least 24 weeks for primary evaluation and up to 52 weeks for extended assessments. During the study, participants undergo regular assessments including tumor measurements by CT or MRI, biopsies for PD-L1 testing, and laboratory evaluations of organ function. Researchers monitor pharmacokinetics, efficacy, safety, and immunogenicity over the treatment period. Participants are followed through scheduled visits with evaluations up to one year, with continued safety monitoring and data collection until study completion in 2029.
CONDITIONS
Brief Title
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Research Team
S
Susana Millán, PhD
C
Camino Huerga
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here